Skip to main content
Top
Published in: Diabetologia 6/2021

Open Access 01-06-2021 | Type 2 Diabetes | Article

Productivity-adjusted life years lost due to type 2 diabetes in Germany in 2020 and 2040

Authors: Thaddäus Tönnies, Annika Hoyer, Ralph Brinks

Published in: Diabetologia | Issue 6/2021

Login to get access

Abstract

Aims/hypothesis

Type 2 diabetes can lead to reduced productivity during working age. We aimed to estimate productive life years lost associated with type 2 diabetes on the individual and population level in Germany in 2020 and 2040, while accounting for future trends in mortality.

Methods

Based on a mathematical projection model, we estimated age- and sex-specific productivity losses associated with type 2 diabetes during working age (20–69 years) in Germany in 2020 and 2040. Productivity losses in terms of excess mortality (years of life lost, YLL) and reductions in labour force participation, presenteeism and absenteeism (years of productivity lost, YPL) were summed to calculate productivity-adjusted life years (PALY) lost. Input data for the projection were based on meta-analyses, representative population-based studies and population projections to account for future trends in mortality.

Results

Compared with a person without type 2 diabetes, mean PALY lost per person with type 2 diabetes in 2020 was 2.6 years (95% CI 2.3, 3.0). Of these 2.6 years, 0.4 (95% CI 0.3, 0.4) years were lost due to YLL and 2.3 (95% CI 1.9, 2.6) years were lost due to YPL. Age- and sex-specific results show that younger age groups and women are expected to lose more productive life years than older age groups and men. Population-wide estimates suggest that 4.60 (95% CI 4.58, 4.63) million people with prevalent type 2 diabetes in 2020 are expected to lose 12.06 (95% CI 10.42, 13.76) million PALY (1.62 million years due to YLL and 10.44 million years due to YPL). In 2040, individual-level PALY lost are projected to slightly decrease due to reductions in YLL. In contrast, population-wide PALY lost are projected to increase to 15.39 (95% CI 13.19, 17.64) million due to an increase in the number of people with type 2 diabetes to 5.45 (95% CI 5.41, 5.50) million.

Conclusions/interpretation

On the population level, a substantial increase in productivity burden associated with type 2 diabetes was projected for Germany between 2020 and 2040. Efforts to reduce the incidence rate of type 2 diabetes and diabetes-related complications may attenuate this increase.

Graphical abstract

Appendix
Available only for authorised users
Literature
16.
go back to reference Schmidt C, Reitzle L, Dreß J, Rommel A, Ziese T, Heidemann C (2020) Prevalence and incidence of documented diabetes based on health claims data-reference analysis for diabetes surveillance in Germany. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 63:93–102 [article in German]. https://doi.org/10.1007/s00103-019-03068-9CrossRef Schmidt C, Reitzle L, Dreß J, Rommel A, Ziese T, Heidemann C (2020) Prevalence and incidence of documented diabetes based on health claims data-reference analysis for diabetes surveillance in Germany. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 63:93–102 [article in German]. https://​doi.​org/​10.​1007/​s00103-019-03068-9CrossRef
17.
go back to reference National Diabetes-Surveillance at the Robert Koch Institute (2019) Diabetes in Germany – National Diabetes-Surveillance Report 2019. Available from http://diabsurv.rki.de. Accessed 1 Apr 2020 National Diabetes-Surveillance at the Robert Koch Institute (2019) Diabetes in Germany – National Diabetes-Surveillance Report 2019. Available from http://​diabsurv.​rki.​de. Accessed 1 Apr 2020
18.
go back to reference Rosenbauer J, Neu A, Rothe U, Seufert J, Holl RW (2019) Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents. J Health Monit 4(2). https://doi.org/10.25646/5987 Rosenbauer J, Neu A, Rothe U, Seufert J, Holl RW (2019) Types of diabetes are not limited to age groups: type 1 diabetes in adults and type 2 diabetes in children and adolescents. J Health Monit 4(2). https://​doi.​org/​10.​25646/​5987
24.
go back to reference Heidemann C, Scheidt-Nave C (2017) Prevalence, incidence and mortality of diabetes mellitus in adults in Germany – A review in the framework of the Diabetes Surveillance. Journal of Health Monitoring 2:98–121 Heidemann C, Scheidt-Nave C (2017) Prevalence, incidence and mortality of diabetes mellitus in adults in Germany – A review in the framework of the Diabetes Surveillance. Journal of Health Monitoring 2:98–121
30.
go back to reference Sørensen J, Ploug UJ (2013) The cost of diabetes-related complications: registry-based analysis of days absent from work. Economics Research International 2013:618039CrossRef Sørensen J, Ploug UJ (2013) The cost of diabetes-related complications: registry-based analysis of days absent from work. Economics Research International 2013:618039CrossRef
Metadata
Title
Productivity-adjusted life years lost due to type 2 diabetes in Germany in 2020 and 2040
Authors
Thaddäus Tönnies
Annika Hoyer
Ralph Brinks
Publication date
01-06-2021
Publisher
Springer Berlin Heidelberg
Keyword
Type 2 Diabetes
Published in
Diabetologia / Issue 6/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05409-3

Other articles of this Issue 6/2021

Diabetologia 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.